M&G USA Corporation
USPTO PatentsView assignee record - 7 granted patents across 14 technology areas, recorded in grant years 2015–2017. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C08L (Compositions OF Macromolecular Compounds).
The verdict
According to USPTO PatentsView, M&g ranks #36,467 of 49,997 tracked US assignees by granted-patent volume, with 7 patents across 14 technology areas.
- #36,467
- of 49,997 US assignees by volume
- 32nd percentile
- by Innovation Score (29.8/100)
- 15.6
- avg claims per patent
- -100%
- grant velocity, last 5 yrs
USPTO PatentsView assignee plate
Corpus R36467 · US Corporation #36,467 · 7 grants
GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-FOCUS · INNOV-THIN · CLAIMS-RICH · TYPE-USCORP · VEL-DROP · BOOK-FULL
- GRANTS-MICRO 7 grants
- MID-PACK #36,467/49,997
- PHOTO-FINISH Lysosomal Therapeutics
- CPC-FOCUS C08L · 14 areas
- INNOV-THIN 29.8/100
- CLAIMS-RICH 15.6 claims/avg
- TYPE-USCORP US Corporation
- VEL-DROP -100% vel
- BOOK-FULL 10/10 fields
Nearest grant-volume peer: Lysosomal Therapeutics Inc. (±0 grants)
Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.
How M&g’s 29.8 Innovation Score adds up
The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.
Innovation-score neighbourhood around M&g
Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.
- Qualcomm Incorporated · highest
Qualcomm Incorporated · highest
85 score
- M&G USA · this assignee 30
M&G USA · this assignee
30 score
- 3D Lighting… · lowest 7
3D Lighting… · lowest
7 score
What this shows M&g's Innovation Score is 29.8/100 (32nd percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.
Does more volume mean deeper claims for M&g?
Each dot is one of M&g’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). M&g’s own 15.6 claims/patent is at or below the 16.0 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.
Where M&g's grants concentrate
M&G USA Corporation is a focused PatentsView assignee: 14 CPC subclasses with 85.7% of grants classified under C08L (Compositions OF Macromolecular Compounds). Peak complete grant year is 2015 (4 grants) versus a trough of 1 in 2016. By volume, M&g sits between Lysosomal Therapeutics Inc. and M.A.E. S.p.A..
Who files at M&G's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- Lysosomal Therape…
Lysosomal Therapeutics Inc.
7 patents
- M & Q IP Leasing
M & Q IP Leasing, LLC
7 patents
- M Cubed
M Cubed Technologies, Inc.
7 patents
- M et P Pharma
M et P Pharma AG
7 patents
- M&M Oil Tools
M&M Oil Tools, LLC
7 patents
- M-edge Internatio…
M-Edge International Corporation
7 patents
- M-tec
M-tec Co., Ltd.
7 patents
- M A E S p A
M.A.E. S.p.A.
7 patents
- M&G USA ◀
M&G USA Corporation
7 patents
What this shows M&G holds 7 patents at rank #36,312, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near M&G
By rank, the assignees closest to #36,312 in granted patent volume.
- Lysosomal Therapeutics Inc. #36,308 · 7 patents
- M & Q IP Leasing, LLC #36,309 · 7 patents
- M Cubed Technologies, Inc. #36,310 · 7 patents
- M et P Pharma AG #36,311 · 7 patents
- M&M Oil Tools, LLC #36,313 · 7 patents
- M-Edge International Corporation #36,314 · 7 patents
- M-tec Co., Ltd. #36,315 · 7 patents
- M.A.E. S.p.A. #36,316 · 7 patents
Leaders in C08L (Compositions OF Macromolecular Compounds)
Other assignees with the most granted patents in M&G's primary technology class.
M&g's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
30 32nd percentile higher than 32% of 49,997 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2015 | 4 | 57.1% |
| 2016 | 1 | 14.3% |
| 2017 | 2 | 28.6% |
Which technologies does M&G USA Corporation patent most?
Top 14 of 14 technology areas
Data Source
USPTO PatentsView, US granted patents 2015–2025
What to do with this data
M&G USA Corporation's patent record in context - here's where to go next.
- M&G USA Corporation's lead technology class is C08L (Compositions OF Macromolecular Compounds), 85.7% of its portfolio - see every assignee active in that class. Explore C08L
- Ranked #36,467 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
- Compare M&G USA Corporation against Lysosomal Therapeutics Inc., an assignee filing at a similar volume. Compare portfolios
- Innovation Score of 29.8/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated
Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.